179 related articles for article (PubMed ID: 28558055)
1. Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.
Tang KT; Hsieh TY; Chao YH; Lin MX; Chen YH; Chen DY; Lin CC
PLoS One; 2017; 12(5):e0178404. PubMed ID: 28558055
[TBL] [Abstract][Full Text] [Related]
2. Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.
Manganelli V; Truglia S; Capozzi A; Alessandri C; Riitano G; Spinelli FR; Ceccarelli F; Mancuso S; Garofalo T; Longo A; Valesini G; Sorice M; Conti F; Misasi R
Front Immunol; 2019; 10():460. PubMed ID: 30923525
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis in patients with primary antiphospholipid antibody syndrome.
Tang KT; Hsieh TY; Chao YH; Li JP; Lan JL; Lin CC; Chen DY
Int J Rheum Dis; 2019 Apr; 22(4):677-685. PubMed ID: 30729698
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
Basta G; Del Turco S; Navarra T; Lee WM;
Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
[TBL] [Abstract][Full Text] [Related]
5. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
[TBL] [Abstract][Full Text] [Related]
6. Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis.
Yu SL; Wong CK; Szeto CC; Li EK; Cai Z; Tam LS
Lupus; 2015 Jun; 24(7):675-86. PubMed ID: 25411258
[TBL] [Abstract][Full Text] [Related]
7. Elevated Serum Level of HMGB1 in Patients with the Antiphospholipid Syndrome.
Manganelli V; Capozzi A; Truglia S; Alessandri C; Lococo E; Garofalo T; De Carolis C; Conti F; Valesini G; Sorice M; Longo A; Misasi R
J Immunol Res; 2017; 2017():4570715. PubMed ID: 29410969
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.
Kocsis AK; Szabolcs A; Hofner P; Takács T; Farkas G; Boda K; Mándi Y
Pancreatology; 2009; 9(4):383-91. PubMed ID: 19451748
[TBL] [Abstract][Full Text] [Related]
9. The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus.
Ma CY; Ma JL; Jiao YL; Li JF; Wang LC; Yang QR; You L; Cui B; Chen ZJ; Zhao YR
Scand J Immunol; 2012 Jun; 75(6):614-22. PubMed ID: 22324318
[TBL] [Abstract][Full Text] [Related]
10. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
11. Functional role of soluble receptor for advanced glycation end products in stroke.
Tang SC; Wang YC; Li YI; Lin HC; Manzanero S; Hsieh YH; Phipps S; Hu CJ; Chiou HY; Huang YS; Yang WS; Mattson MP; Arumugam TV; Jeng JS
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):585-94. PubMed ID: 23288172
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome.
Patsouras MD; Sikara MP; Grika EP; Moutsopoulos HM; Tzioufas AG; Vlachoyiannopoulos PG
J Autoimmun; 2015 Dec; 65():30-7. PubMed ID: 26283469
[TBL] [Abstract][Full Text] [Related]
13. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
14. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease.
Chen DY; Chen YM; Lin CC; Hsieh CW; Wu YC; Hung WT; Chen HH; Lan JL
BMC Musculoskelet Disord; 2015 May; 16():111. PubMed ID: 25956266
[TBL] [Abstract][Full Text] [Related]
15. Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension.
Suzuki S; Nakazato K; Sugimoto K; Yoshihisa A; Yamaki T; Kunii H; Suzuki H; Saitoh S; Takeishi Y
Int Heart J; 2016; 57(2):234-40. PubMed ID: 26973260
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
[TBL] [Abstract][Full Text] [Related]
17. Effects of bone marrow MSCs transfected with sRAGE on the intervention of HMGB1 induced immuno-inflammatory reaction.
Wang J; Wang H; Shi J; Ding Y
Int J Clin Exp Pathol; 2015; 8(10):12028-40. PubMed ID: 26722388
[TBL] [Abstract][Full Text] [Related]
18. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset.
Glasnović A; Cvija H; Stojić M; Tudorić-Đeno I; Ivčević S; Romić D; Tičinović N; Vuletić V; Lazibat I; Grčević D
Neuroimmunomodulation; 2014; 21(5):226-33. PubMed ID: 24603633
[TBL] [Abstract][Full Text] [Related]
19. Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome.
Alvarez-Rodriguez L; Riancho-Zarrabeitia L; Calvo-Alén J; López-Hoyos M; Martínez-Taboada V
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462939
[TBL] [Abstract][Full Text] [Related]
20. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
